MIRA INFORM REPORT

 

 

Report No. :

311967

Report Date :

14.03.2015

 

IDENTIFICATION DETAILS

 

Name :

PHARMAMATCH B.V.

 

 

Registered Office :

Egelenburg 2, 1081GK Amsterdam

 

 

Country :

Netherlands

 

 

Financials (as on) :

31.12.2013

 

 

Date of Incorporation :

17.04.2007

 

 

Com. Reg. No.:

34272144

 

 

Legal Form :

Private Company

 

 

Line of Business :

·         Agents specializing in the sale of other goods

·         Wholesale of pharmaceutical goods

 

 

No. of Employees :

12

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

Slow but correct

Litigation :

Clear

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – December 31, 2014

 

Country Name

Previous Rating

(30.09.2014)

Current Rating

(31.12.2014)

Netherlands

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

NETHERLANDS - ECONOMIC OVERVIEW

 

Netherlands is the sixth-largest economy in the euro-zone and is noted for its stable industrial relations, moderate unemployment and inflation, sizable trade surplus, and important role as a European transportation hub. Industrial activity is predominantly in food processing, chemicals, petroleum refining, and electrical machinery. A highly mechanized agricultural sector employs only 2% of the labor force but provides large surpluses for the food-processing industry and for exports. Netherlands, along with 11 of its EU partners, began circulating the euro currency on 1 January 2002. The Dutch financial sector suffered as a result of the global financial crisis, due in part to the high exposure of some Dutch banks to US mortgage-backed securities. In 2008, the government nationalized two banks and injected billions of dollars of capital into other financial institutions, to prevent further deterioration of a crucial sector. After 26 years of uninterrupted economic growth, the Dutch economy - highly dependent on an international financial sector and international trade - contracted by 3.5% in 2009. To recover, the government sought to boost the domestic economy by accelerating infrastructure programs, offering corporate tax breaks for employers to retain workers, and expanding export credit facilities. The stimulus programs and bank bailouts, however, resulted in a government budget deficit of 5.3% of GDP in 2010 that contrasted sharply with a surplus of 0.7% in 2008. The government of Prime Minister Mark RUTTE began implementing austerity measures in early 2011, mainly reducting expenditures, which resulted in an improved budget deficit in 2011. However, in 2012 tax revenues dropped, GDP contracted, and the budget deficit deteriorated. In 2013, the government budget deficit decreased to 3.3% of GDP due to increased government revenue from higher taxes. However, spending on social benefits also increased, due to a rise in unemployment benefits and payments for pensions. The high unemployment rate and tax increases have contributed to continued decreases in household disposable income, causing the Dutch economy to contract.

 

Source : CIA

Summary

 

Company name                        PharmaMatch B.V.

Operative address                    Egelenburg 2

1081GK Amsterdam

Netherlands

Legal form                               Private Company

Registration number                KvK-nummer: 34272144

VAT-number                             817892448

 

Year

 

2013

Mutation

2012

Mutation

2011

Fixed assets

173.707

-2,10

177.437

101,93

87.872

Total receivables

1.024.762

36,13

752.789

-1,07

760.946

Total equity

411.025

23,96

331.577

-9,93

368.147

Short term liabilities

900.041

59,29

565.039

5,75

534.303

Working capital

255.444

35,19

188.952

-32,58

280.275

Quick ratio

1,28

-3,76

1,33

-12,50

1,52

 

 

 

 

Contact information

 

Company name                        PharmaMatch B.V.

Trade names                            PharmaMatch B.V.

Operative address                    Egelenburg 2

1081GK Amsterdam

Netherlands

Correspondence address         Egelenburg 2

1081GK Amsterdam

Netherlands

Telephone number                   0203011180

Email address                          info@pharmamatch.nl

Website                                    www.pharmamatch.nl

 

 

Registration

 

Registration number                            KvK-nummer: 34272144

Branch number                                    000016426053

VAT-number                                         817892448

Status                                                  Active

First registration company register      2007-04-19

Memorandum                                       2007-04-17

Establishment date                              2007-04-17

Legal form                                           Private Company

Issued placed capital                           EUR 18.000

Paid up share capital                           EUR 18.000

 

 

Activities

 

SBI                                                       Agents specializing in the sale of other goods (4618)

Wholesale of pharmaceutical goods (46461)

Accounting (69105)

Organizational planning (70221)

Exporter                                               Yes

Importer                                               Yes

Branche organisations                         BOGIN - Bond van de Generieke Geneesmiddelenindustrie in Nederland

Goal                                                     Obtaining and managing patent rights or other similar rights . Engaging in trading and marketing activities and negotiating sales of pharmaceutical (end) products . The provision of advisory services. Import and Export pharmaceutical (end) products ( wholesale ) .

 

 

Relations

 

Shareholders                                       PharmaMatch Tussenholding B.V.

Egelenburg 2

1081GK AMSTERDAM

Netherlands

Registration number: 343634910000

Percentage: 100%

PharmaMatch Holding B.V.

Registration number: 332889340000

PharmaMatch R&D B.V.

Registration number: 342654270000

EMP Europe B.V.

Registration number: 342829710000

Companies on same address

PharmaMatch Tussenholding B.V.

Registration number: 343634910000

 

 

Management

 

Active management                              PharmaMatch Holding B.V.

Egelenburg 2

1081GK Amsterdam

Netherlands

Registration number: 332889340000

Competence: Fully authorized

Function: General Director

Starting date: 2007-04-17

 

Employees

 

Total according to the Chamber of Commerce             12

 

Year

 

2015

2014

2013

2012

2011

Total

12

12

12

3

3

 

 

 

Payments

 

Description                  Overeenkomstig conditie

 

 

Year

2013

2012

2011

2010

2009

Quick ratio

1,28

1,33

1,52

1,47

1,64

Current ratio

1,28

1,33

1,52

1,47

1,64

Working capital/ balance total

0,19

0,20

0,31

0,28

0,34

Equity / balance total

0,31

0,36

0,41

0,40

0,47

Equity / Fixed assets

2,37

1,87

4,19

3,32

3,63

Equity / liabilities

0,45

0,55

0,69

0,67

0,88

Balance total / liabilities

1,45

1,55

1,69

1,67

1,88

Working capital

255.444

188.952

280.275

227.969

193.835

Equity

411.025

331.577

368.147

326.386

267.533

Mutation equity

23,96

-9,93

12,79

22,00

-13,69

Mutation short term liabilities

59,29

5,75

9,47

59,97

-0,32

 

 

 

Summary

 

The 2013 financial result structure is a postive working captial of 255.444 euro, which is in

agreement with 19 % of the total assets of the company.

The working capital has increase with 35.19 % compared to previous year. The ratio with

respect to the total assets of the company has however, declined.

The improvement between 2012 and 2013 has mainly been caused by a current liabilities

reduction.

The current ratio of the company in 2013 was 1.28. When the current ratio is below 1.5, the

company may have problems meeting its short-term obligations.

The quick ratio in 2013 of the company was 1.28. A company with a Quick Ratio of more than

1 can currently pay back its current liabilities.

The 2012 financial result structure is a postive working captial of 188.952 euro, which is in

agreement with 20 % of the total assets of the company.

The working capital has diminished with -32.58 % compared to previous year. The ratio, with

respect to the total assets of the company has however, declined.

The deterioration between 2011 and 2012 has mainly been caused by an increase of the

current liabilities.

The current ratio of the company in 2012 was 1.33. When the current ratio is below 1.5, the

company may have problems meeting its short-term obligations.

The quick ratio in 2012 of the company was 1.33. A company with a Quick Ratio of more than

1 can currently pay back its current liabilities.

 

 

 

 

 

Financial statement

 

Last annual account                 2013

Remark annual account            The company is obliged to file its financial statements.

Type of annual account            Corporate

Annual account                        PharmaMatch B.V.

Egelenburg 2

1081GK Amsterdam

Netherlands

Registration number: 342721440000

 

Balance

 

Year

 

2013

2012

2011

2010

2009

End date

2013-12-31

2012-12-31

2011-12-31

2010-12-31

2009-12-31

Intangible fixed assets

15.000

18.000

21.000

24.000

27.000

Tangible fixed assets

158.707

159.437

66.872

74.417

46.698

Fixed assets

173.707

177.437

87.872

98.417

73.698

Total receivables

1.024.762

752.789

760.946

714.573

424.513

Liquid funds

130.723

1.202

53.632

1.483

74.434

Current assets

1.155.485

753.991

814.578

716.056

498.947

Total assets

1.329.192

931.428

902.450

814.473

572.645

Issued capital

18.000

18.000

18.000

18.000

18.000

Share premium reserve

182.000

 

182.000

182.000

182.000

Legal and statutory reserve

 

182.000

 

 

 

Other reserves

211.025

131.577

168.147

126.386

67.533

Total reserves

393.025

313.577

350.147

308.386

249.533

Total equity

411.025

331.577

368.147

326.386

267.533

Long term interest yielding debt

18.126

34.812

 

 

 

Long term liabilities

18.126

34.812

 

 

 

Short term liabilities

900.041

565.039

534.303

488.087

305.112

Total short and long term liabilities

918.167

599.851

534.303

488.087

305.112

Total liabilities

1.329.192

931.428

902.450

814.473

572.645

 

 

Summary

 

The total assets of the company increased with 42.7 % between 2012 and 2013.

Despite the assets growth, the non current assets decreased with -2.1 %.

The asset growth has mainly been financed by a debt increase of 53.07 %. The Net Worth,

however, grew with 23.96 %.

In 2013 the assets of the company were 13.07 % composed of fixed assets and 86.93 % by

current assets. The assets are being financed by an equity of 30.92 %, and total debt of

69.08 %.

The total assets of the company increased with 3.21 % between 2011 and 2012.

The total asset increase is retrievable in the fixed asset growth of 101.93 %.

Asset growth is in contrasts with the net worth decline of -9.93 %. The company's

indebtedness has, therefore, increased with 12.27 %.

In 2012 the assets of the company were 19.05 % composed of fixed assets and 80.95 % by

current assets. The assets are being financed by an equity of 35.6 %, and total debt of 64.4 %.

 

 

 

 

Analysis

 

Branch (SBI)                             Holding companies (not financial) (70)

Region                                     Groot Amsterdam

In the Netherlands 164954 of the companies are registered with the SBI code 70

In the region Groot Amsterdam 18004 of the companies are registered with the SBI code 70

In the Netherlands 1108 of the bankrupcties are published within this sector

In the region Groot Amsterdam 85 of the bankruptcies are published within this sector

The risk of this specific sector in the Netherlands is Low

The risk of this specific sector in the region Groot Amsterdam is Low

 

Publications

 

Filings                                     11-08-2014: De jaarrekening over 2013 is gepubliceerd.

15-07-2013: De jaarrekening over 2012 is gepubliceerd.

18-10-2012: De jaarrekening over 2011 is gepubliceerd.

01-09-2011: De jaarrekening over 2010 is gepubliceerd.

08-06-2010: De jaarrekening over 2009 is gepubliceerd.

 

 

Company structure

 

Relations                      4

 

PharmaMatch Holding B.V.

Egelenburg 2

1081GK Amsterdam

Netherlands

Registration number: 332889340000

 

• PharmaMatch Tussenholding B.V.

Egelenburg 2

1081GK AMSTERDAM

Netherlands

Registration number: 343634910000

 

• PharmaMatch B.V.

Egelenburg 2

1081GK Amsterdam

Netherlands

Registration number: 342721440000

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.62.67

UK Pound

1

Rs.93.16

Euro

1

Rs.66.42

 

 

INFORMATION DETAILS

 

Analysis Done by :

DIV

 

 

Report Prepared by :

TPT

 

               


 

RATING EXPLANATIONS

 

RATING

STATUS

PROPOSED CREDIT LINE

 

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

 

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

 

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

 

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

 

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

 

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

 

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

Credit not recommended

 

--

NB

New Business

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.